BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterineHematology & OncologyPulmonologyPharmacyBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerUterine CancerCancerOpdivo
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, April 3, 2017 (HealthDay News) -- For patients with pretreated advanced non-small-cell lung cancer (NSCLC), nivolumab is associated with a five-year overall survival rate of 16 percent, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 1 to 5 in Washington, D.C.
Julie Brahmer, M.D., from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, and colleagues reported updated results from the CA209-003 study based on a five-year follow-up for an immune checkpoint inhibitor. One hundred twenty-nine patients with heavily pretreated advanced NSCLC received nivolumab every two weeks for up to 96 weeks. Patients were followed for a minimum of 58.25 months.
The researchers found that the five-year overall survival rate in all patients was 16 percent. Patients with squamous and nonsquamous NSCLC had similar overall survival rates at five years (16 and 15 percent, respectively). Nine of the 16 patients who survived five years or more were male and 12 were current smokers at baseline. Nine of the 16 patients completed the maximum number of nivolumab cycles per protocol. Twelve patients had received no further therapy after stopping nivolumab and were without evidence of progressive disease at five years.
"We are performing further studies to learn why these patients did so well for so long and better understand which patients can stop treatment at two years and which of them need to continue treatment beyond two years," Brahmer said in a statement.
One author disclosed financial ties to Bristol-Myers Squibb, which manufactures nivolumab and funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 29, 2022
Read this Next
Other Trending Articles